The objective of this study was to evaluate whether belinostat could be an interesting pharmacological tool to increase the expression of Bim, Puma, and/or Noxa, and to induce apoptosis in ovarian cancers, either alone or in combination with strategies targeting Bcl‐xL or Mcl‐1. Here, BCL2L11 is linked to ovarian cancer.